<DOC>
	<DOCNO>NCT02387138</DOCNO>
	<brief_summary>This study determine Maximal Tolerated Dose ( MTD ) , Dose Limitant Toxicities ( DLTs ) safety profile S-1 combine fixed dos Irinotecan ( SIRI schedule ) fix dos Irinotecan Oxaliplatin ( SIRINOX schedule ) .</brief_summary>
	<brief_title>A Trial Assessing Several Schedules Oral S-1 Combination With Fixed Dose Oxaliplatin Irinotecan</brief_title>
	<detailed_description>Given therapeutic potential reduce toxicity advantage S-1 compare fluoropyrimidines , trial assess S-1 Oxaliplatin plus Irinotecan warrant future investigation ( Phase II-III ) . The primary objective determine Maximal Tolerated Dose ( MTD ) , Dose Limitant Toxicities ( DLTs ) safety profile S-1 combine fixed dos Irinotecan ( SIRI schedule ) fix dos Irinotecan Oxaliplatin ( SIRINOX schedule ) .</detailed_description>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Male female ≥ 18 year old Histologically confirm diagnosis advance metastatic digestive adenocarcinoma ( gastroesophageal adenocarcinoma , colorectal adenocarcinoma , pancreatic adenocarcinoma , cholangiocarcinoma , hepatocarcinoma ) Metastatic advance disease eligible curative surgery No active biliary obstruction Previous adjuvant chemotherapy allow . It must complete least 6 month start study treatment First line chemotherapy allow ( exclude chemotherapy Capecitabine 5 FU Irinotecan Oxaliplatin ) . Previous Oxaliplatin allow patient receive SIRI A fourweek washout period since prior treatment One measurable metastatic lesion ECOG status ≤ 1 Total bilirubin ≤ 1.5 Upper limit normal ( ULN ) , ALT AST ≤ 2.5 ULN ( &lt; 5 case liver impairment ) Haemoglobin ≥ 10 g/dL , neutrophils ≥ 1,500/mm3 , platelet ≥ 100,000/mm3 white blood cell &gt; 3000 /mm3 Lipase &lt; 1.5 ULN , serum creatinine ≤ 1.5 ULN Negative pregnancy test woman childbearing potential Use effective contraceptive method whole treatment 3 month completion treatment Life expectancy &gt; 3 month Informed consent form ( ICF ) sign prior study specific procedure Patients must affiliate Social Security System History previous treatment Oxaliplatin except SIRI , Irinotecan , 5 FU Capecitabine firstline chemotherapy Peripheral sensory neuropathy ≥ grade 2 time sign ICF Known central nervous system metastases Unique bone metastasis History presence cancer within past 5 year ( except curatively treat nonmelanoma skin cancer ) Patients known deficiency enzyme dihydropyrimidine dehydrogenase ( DPD ) , well patient , within previous four week , treat medicine inhibits enzyme Patients rare hereditary problem galactose intolerance , lactase deficiency glucose galactose malabsorption Malabsorption syndrome disease significantly affect gastrointestinal function Patient dysphagia inability swallow tablet Inflammatory bowel disease chronic diarrhoea ( Grade ≥ 2 NCI CTC V4.03 ) History organ transplantation use immunosuppression therapy Concomitant severe infection ( &gt; grade 2 NCI.CTCAE v4.03 ) major organ failure Active cardiac disease , angina pectoris myocardial infarction last 6 month Renal disease Unstable diabetes Creatinine clearance &lt; 50 ml/min calculate use MDRD formula Pregnant breastfeed woman Participation another clinical trial within 30 day prior study entry Psychological , social , geographical condition would preclude study compliance ( treatment administration study followup ) Legal incapacity physical , psychological mental status interfere patient 's ability sign inform consent terminate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>